Related Experiment Video

Updated: Jan 1, 2026

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.1K

Effects of nicorandil infusion on ECG parameters in patients with unstable angina pectoris and percutaneous coronary

Weiding Wang1, Xu Zhang1, Kangyin Chen1

  • 1Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.

Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
|December 19, 2019
PubMed

Insights

Nicorandil infusion effectively reduced QTd and Tp-e intervals in patients with unstable angina undergoing percutaneous coronary intervention. This study highlights nicorandil

Area of Science:

  • Cardiology
  • Clinical Electrophysiology
  • Pharmacology

Background:

  • Percutaneous coronary intervention (PCI) effectively treats acute coronary syndrome (ACS) but carries risks.
  • Nicorandil, an anti-anginal drug, enhances microvascular circulation and coronary blood flow.
  • Unstable angina pectoris (UA) is a critical condition requiring effective management during PCI.

Purpose of the Study:

  • To evaluate the impact of nicorandil on electrocardiogram (ECG) parameters in UA patients undergoing PCI.
  • To assess the effects of intracoronary and intravenous nicorandil administration.
  • To determine if nicorandil influences electrophysiological measures post-PCI.

Main Methods:

  • A single-center, self-controlled clinical trial involving 63 UA patients undergoing PCI.
  • Patients were divided into control, short-term nicorandil, and prolonged nicorandil groups.
  • ECG parameters, including QTd and Tp-e intervals, were analyzed before and 24 hours after nicorandil infusion.

Main Results:

  • No significant differences in baseline clinical characteristics or ECG parameters among the groups.
  • Nicorandil treatment significantly shortened QTd and Tp-e intervals post-PCI compared to the control group.
  • These electrophysiological changes were observed in both short-term and prolonged nicorandil administration groups.

Conclusions:

  • Nicorandil infusion demonstrably reduces QTd and Tp-e intervals in UA patients post-PCI.
  • These findings suggest a potential benefit of nicorandil in managing electrophysiological disturbances.
  • Further research is warranted to confirm if these changes correlate with reduced ventricular arrhythmias and improved clinical outcomes.
Abstract

Keywords:
QT dispersionTp-e intervalnicorandilunstable angina pectoris

More Related Videos

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.7K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K

Related Concept Videos

Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
254
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
182
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.3K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.2K
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
169
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
234